Skip to main content

Table 2 Intracellular and plasma cytokines and chemokines by age, analyzed by multivariate random-effect models estimated by stepwise procedure and adjusted by previous episodes, current infection, IPTi treatment, gender and neighborhood of residence.

From: Intermittent preventive treatment with sulfadoxine-pyrimethamine does not modify plasma cytokines and chemokines or intracellular cytokine responses to Plasmodium falciparum in Mozambican Children

Cytokines and chemokines

Age (months)

Proportional difference

95% CI

P value*

Overall P value

Intracellular

IFN-γ

5

1

-

-

< 0.0001

  

9

0.36

0.26; 0.48

< 0.0001

 
  

12

0.41

0.29; 0.57

< 0.0001

 
  

24

0.32

0.23; 0.45

< 0.0001

 
 

IL-10

5

1

-

-

< 0.0001

  

9

0.45

0.37; 0.55

< 0.0001

 
  

12

0.63

0.50; 0.78

< 0.0001

 
  

24

0.92

0.74; 1.15

0.4700

 

Plasma

IL-2

5

1

-

-

< 0.0001

  

9

0.74

0.58; 0.95

0.0193

 
  

12

0.47

0.37; 0.60

< 0.0001

 
  

24

0.38

0.29; 0.51

< 0.0001

 
 

IL-12

5

1

-

-

0.0001

  

9

0.87

0.69; 1.10

0.2428

 
  

12

0.63

0.50; 0.79

0.0001

 
  

24

1.02

0.79; 1.31

0.9070

 
 

IFN-γ

5

1

-

-

< 0.0001

  

9

0.84

0.59; 1.21

0.3510

 
  

12

0.43

0.30; 0.61

< 0.0001

 
  

24

0.69

0.47; 1.03

0.0703

 
 

IL-1β

5

1

-

-

< 0.0001

  

9

0.30

0.22; 0.40

< 0.0001

 
  

12

0.36

0.27; 0.48

< 0.0001

 
  

24

0.51

0.38; 0.70

< 0.0001

 
 

IL-6

5

1

-

-

0.0001

  

9

0.51

0.38; 0.68

< 0.0001

 
  

12

0.65

0.49; 0.87

0.0032

 
  

24

0.75

0.55; 1.03

0.0806

 
 

TNF

5

1

-

-

< 0.0001

  

9

0.54

0.39; 0.73

0.0001

 
  

12

0.39

0.29; 0.53

< 0.0001

 
  

24

0.21

0.15; 0.30

< 0.0001

 
 

IL-4

5

1

-

-

< 0.0001

  

9

0.69

0.53; 0.90

0.0073

 
  

12

0.54

0.41; 0.71

< 0.0001

 
  

24

0.31

0.23; 0.41

< 0.0001

 
 

IL-5

5

1

-

-

0.0001

  

9

0.88

0.75; 1.04

0.1450

 
  

12

0.68

0.58; 0.81

< 0.0001

 
  

24

0.77

0.65; 0.93

0.0056

 
 

IL-13

5

1

-

-

< 0.0001

  

9

0.77

0.64; 0.92

0.0045

 
  

12

0.58

0.49; 0.70

< 0.0001

 
  

24

1.59

1.30; 1.94

< 0.0001

 
 

IL-10

5

1

-

-

< 0.0001

  

9

0.85

0.71; 1.03

0.0941

 
  

12

0.60

0.50; 0.73

< 0.0001

 
  

24

0.53

0.43; 0.66

< 0.0001

 
 

IL-7

5

1

-

-

< 0.0001

  

9

0.99

0.86; 1.15

0.9244

 
  

12

0.74

0.64; 0.86

< 0.0001

 
  

24

0.66

0.56; 0.77

< 0.0001

 
 

IL-17

5

1

-

-

< 0.0001

  

9

0.68

0.54; 0.85

0.0009

 
  

12

0.63

0.50; 0.79

0.0001

 
  

24

1.05

0.82; 1.35

0.6774

 
 

G-CSF

5

1

-

-

< 0.0001

  

9

0.77

0.64; 0.91

0.0032

 
  

12

0.64

0.53; 0.76

< 0.0001

 
  

24

1.50

1.24; 1.81

< 0.0001

 
 

GM-CSF

5

1

-

-

< 0.0001

  

9

0.78

0.56; 1.09

0.1525

 
  

12

0.49

0.35; 0.68

< 0.0001

 
  

24

0.52

0.36; 0.75

0.0004

 
 

MCP-1

5

1

-

-

< 0.0001

  

9

0.92

0.80; 1.06

0.2724

 
  

12

0.80

0.70; 0.93

0.0025

 
  

24

1.22

1.04; 1.42

0.0156

 
 

MIP-1β

5

1

-

-

< 0.0001

  

9

0.68

0.58; 0.80

< 0.0001

 
  

12

0.85

0.73; 1.00

0.0437

 
  

24

0.98

0.82; 1.16

0.7803

 
 

IL-8

5

1

-

-

0.0003

  

9

0.60

0.47; 0.77

0.0001

 
  

12

0.94

0.73; 1.20

0.6171

 
  

24

0.89

0.68; 1.17

0.3991

 
  1. Intracellular IL-4 is not included (null model). The first P value corresponds to the comparison in between ages and the second corresponds to the overall comparison.
  2. * Each age in relation to 5 months